ITEOS THERAPEUTICS INC (ITOS) Stock Price, Quote, News and Overview
NASDAQ:ITOS - Nasdaq - US46565G1040 - Common Stock - Currency: USD
ITOS Quote, Performance and Key Statistics
7.35
-0.11 (-1.47%)
The current stock price of ITOS is 7.35 USD. In the past month the price increased by 9.62%. In the past year, price decreased by -31.94%.
ITOS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.39 | 329.14B | ||
| AMGN | AMGEN INC | 14.17 | 150.99B | ||
| GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
| ARGX | ARGENX SE - ADR | 330.52 | 37.54B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
| NTRA | NATERA INC | N/A | 20.79B | ||
| BIIB | BIOGEN INC | 7.22 | 17.39B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B |
Related stock screener links
About ITOS
Company Profile
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. The company is headquartered in Watertown, Massachusetts and currently employs 173 full-time employees. The company went IPO on 2020-07-24. The firm is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its advanced program is inupadenant, also known as EOS-850, a next-generation adenosine 2A receptor (A2AR) antagonist tailored to overcome the specific adenosine-mediated immunosuppression found in the tumor microenvironment. Its program to initiate clinical trials is EOS-984, a potentially first-in-class small molecule focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1 (ENT1), a dominant transporter of adenosine on lymphocytes involved in T cell metabolism.
Company Info
ITEOS THERAPEUTICS INC
321 Arsenal Street, Bldg 312, Floor 3, Suite 301
Watertown MASSACHUSETTS 02142 US
CEO: Michel Detheux
Employees: 173
Company Website: https://www.iteostherapeutics.com/
Investor Relations: https://investors.iteostherapeutics.com/
Phone: 18572044583
ITEOS THERAPEUTICS INC / ITOS FAQ
What is the stock price of ITEOS THERAPEUTICS INC today?
The current stock price of ITOS is 7.35 USD. The price decreased by -1.47% in the last trading session.
What is the ticker symbol for ITEOS THERAPEUTICS INC stock?
The exchange symbol of ITEOS THERAPEUTICS INC is ITOS and it is listed on the Nasdaq exchange.
On which exchange is ITOS stock listed?
ITOS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ITEOS THERAPEUTICS INC stock?
12 analysts have analysed ITOS and the average price target is 25.7 USD. This implies a price increase of 249.71% is expected in the next year compared to the current price of 7.35. Check the ITEOS THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ITEOS THERAPEUTICS INC worth?
ITEOS THERAPEUTICS INC (ITOS) has a market capitalization of 280.70M USD. This makes ITOS a Micro Cap stock.
How many employees does ITEOS THERAPEUTICS INC have?
ITEOS THERAPEUTICS INC (ITOS) currently has 173 employees.
What are the support and resistance levels for ITEOS THERAPEUTICS INC (ITOS) stock?
ITEOS THERAPEUTICS INC (ITOS) has a resistance level at 7.36. Check the full technical report for a detailed analysis of ITOS support and resistance levels.
Is ITEOS THERAPEUTICS INC (ITOS) expected to grow?
The Revenue of ITEOS THERAPEUTICS INC (ITOS) is expected to decline by -83.85% in the next year. Check the estimates tab for more information on the ITOS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ITEOS THERAPEUTICS INC (ITOS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ITOS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ITOS, evaluating the profitability, health, valuation and growth aspects
- ITEOS THERAPEUTICS INC (ITOS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ITEOS THERAPEUTICS INC (ITOS) Sales and EPS estimates to see what analysts future expectations are.
- ITEOS THERAPEUTICS INC (ITOS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ITEOS THERAPEUTICS INC (ITOS) Insider and Institutional Ownership to learn about the owners and their transactions.
- ITEOS THERAPEUTICS INC (ITOS) Stock Chart to make your own analysis
- ITEOS THERAPEUTICS INC (ITOS) Latest news and press-releases to stay up to date.
Does ITEOS THERAPEUTICS INC (ITOS) stock pay dividends?
ITOS does not pay a dividend.
When does ITEOS THERAPEUTICS INC (ITOS) report earnings?
ITEOS THERAPEUTICS INC (ITOS) will report earnings on 2025-05-08, before the market open.
What is the Price/Earnings (PE) ratio of ITEOS THERAPEUTICS INC (ITOS)?
ITEOS THERAPEUTICS INC (ITOS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.33).
What is the Short Interest ratio of ITEOS THERAPEUTICS INC (ITOS) stock?
The outstanding short interest for ITEOS THERAPEUTICS INC (ITOS) is 4.85% of its float. Check the ownership tab for more information on the ITOS short interest.
ITOS Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to ITOS. When comparing the yearly performance of all stocks, ITOS is a bad performer in the overall market: 75.13% of all stocks are doing better.
ITOS Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ITOS. ITOS has a great financial health rating, but its profitability evaluates not so good.
ITOS Financial Highlights
Over the last trailing twelve months ITOS reported a non-GAAP Earnings per Share(EPS) of -3.33. The EPS decreased by -5.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.57% | ||
| ROE | -22.77% | ||
| Debt/Equity | 0 |
ITOS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to ITOS. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of -23.31% and a revenue growth -83.85% for ITOS